• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014

  2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vertex Pharmaceuticals Inc. To Contact The Firm

    Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vertex Pharmaceuticals Inc. To Contact The Firm

  3. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  4. How Did Facebook End Up in the S&P 500?

    We dive into the process for adding companies and booting them from the iconic index.

  5. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  6. Best Positioned for Health-Care Reform

    This screen finds companies ready to take advantage when major provisions of law take effect in 2014.

  7. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  8. Morningstar Indexes: Weekly Market Report

    Week ending Oct. 27: Stocks held in check by jump oil prices, weak housing market.

  9. ClearBridge Fund Prepared for Extended Rally

    The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.